scholarly journals Impaired Interferon-Alpha Production by Plasmacytoid Dendritic Cells after Cord Blood Transplantation in Children: Implication for Post-transplantation Toll-Like Receptor Ligand–Based Immunotherapy

2014 ◽  
Vol 20 (10) ◽  
pp. 1501-1507 ◽  
Author(s):  
Emily Charrier ◽  
Paulo Cordeiro ◽  
Rose-Marie Brito ◽  
Michaël Harnois ◽  
Samira Mezziani ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Cord Blood ◽  
Interferon Alpha ◽  
Cord Blood Transplantation ◽  
Plasmacytoid Dendritic Cells ◽  
Toll Like Receptor ◽  
Post Transplantation ◽  
Receptor Ligand ◽  
Blood Transplantation ◽  
Alpha Production

419 Impaired interferon-alpha production by plasmacytoid dendritic cells

2004 ◽  
Vol 40 ◽  
pp. 124
Author(s):  
A. Ulsenheimer ◽  
M.C. Jung ◽  
J.T. Gerlach ◽  
N. Gruener ◽  
C.A. Schirren ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Interferon Alpha ◽  
Plasmacytoid Dendritic Cells ◽  
Alpha Production

scholarly journals Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies

2021 ◽  
Vol 12 ◽  
Author(s):  
Hua Li ◽  
Xiaofan Li ◽  
Yiling Chen ◽  
Duihong Li ◽  
Xianling Chen ◽  
...  
Keyword(s):  
Cord Blood ◽  
Cord Blood Transplantation ◽  
Chronic Gvhd ◽  
Disease Free Survival ◽  
Hematologic Malignancies ◽  
Post Transplantation ◽  
Blood Transplantation ◽  
Gvhd Prophylaxis ◽  
Unrelated Donors ◽  
Unrelated Cord Blood

Allogeneic haploidentical HSCT (haplo-HSCT) and unrelated umbilical cord blood transplantation(UCBT)are used in patients lacking HLA-identical sibling or unrelated donors. With myeloablative condition and GVHD prophylaxis of using low-dose ATG and post-transplantation cyclophosphamide (PTCY), we conducted a prospective clinical trial. Of eligible 122 patients from February 2015 to December 2019 in the study, 113 patients were involved. Forty-eight patients were in the group of sequential haplo-cord transplantation (haplo-cord HSCT), and 65 patients were in the group of single UCBT. The primary endpoint of 2-year disease-free survival (DFS) was no statistical difference between groups (64.1 vs. 56.5%), p>0.05. The analysis of subgroup patients with relapsed/refractory showed haplo-cord HSCT was associated with better OS (HR 0.348, 95% CI, 0.175–0.691; p=0.0025), DFS (HR 0.402, 95% CI, 0.208–0.779; p=0.0069), and GRFS (HR 0.235, 95% CI, 0.120–0.457, p<0.0001) compared to the single cord group. The 2-year’s probability in OS, DFS, and GRFS was 64.9 vs. 31.6%, 64.5 vs. 31.6%, and 60.8 vs. 15.0% in the haplo-cord group and single cord group, respectively. III-IV acute GVHD 8.3 vs. 6.2%, chronic GVHD 25.8 vs. 13.7%, and extensive chronic GVHD 5.3 vs. 1.8% were shown in corresponding group, p>0.05. The patients engrafted persistently with UCB showed better survival outcomes. Our sequential Haplo-cord HSCT with ATG/PTCY improved the survival of patients and might be an alternative transplantation approach for patients with relapsed/refractory hematologic malignancies.

scholarly journals Dendritic Cells in Cord Blood Transplantation: A Review

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Marta Isabel Pereira ◽  
Artur Paiva
Keyword(s):  
Dendritic Cells ◽  
Cord Blood ◽  
Tumor Antigens ◽  
Residual Disease ◽  
Cord Blood Transplantation ◽  
Success Rates ◽  
Innate And Adaptive Immunity ◽  
Blood Transplantation ◽  
Self Tolerance ◽  
Antigen Presenting

Dendritic cells (DCs) are a heterogeneous population of antigen-presenting cells derived from hematopoietic progenitors that bridge the transition between the innate and adaptive immune responses, while maintaining self-tolerance and Th1/Th2 homeostasis, by priming other cells in either an immunogenic or tolerogenic direction. Through their role in both innate and adaptive immunity, DCs play a major part in transplant engraftment and rejection and in graft-versus-host disease (GvHD). Preferentially tolerogenic or immunogenic DC subtypes offer targets for immunotherapy, to optimize transplant success rates and prolong disease-free and overall survival. Cord blood DCs are immature and preferentially tolerogenic, due to maternal-fetal tolerance, leading to better graft acceptance and immune reconstitution and explaining the lower incidence and severity of GvHD in CB transplantation, despite donor-host mismatching. Manipulation of DC maturation and cell loading with tumor-antigens can direct antitumor immunity and target minimal residual disease, as demonstrated for acute myeloid leukemia, optimizing the graft-versus-leukemia effect.

Clinical Significance of EBV-Associated LPD After Cord Blood Transplantation.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 1161-1161
Author(s):  
Maho Satou ◽  
Tomiko Kimoto ◽  
Kayo Yamada ◽  
Osamu Kondou ◽  
Sadao Tokimasa ◽  
...  
Keyword(s):  
Cord Blood ◽  
Conflicts Of Interest ◽  
Hematologic Malignancy ◽  
Cord Blood Transplantation ◽  
Underlying Disease ◽  
Post Transplantation ◽  
Barr Virus ◽  
Blood Transplantation ◽  
Ebv Dna ◽  
Epstein Barr

Abstract Abstract 1161 Poster Board I-183 Introduction The number of cord blood transplantation (CBT) is rapidly increasing. In this setting, development of Epstein-Barr virus (EBV)-associated lymphoproliferative disorder (LPD) appears to be at high risk. To clarify this issue, we retrospectively analyzed EBV serology and clinical course of 57 patients who received CBT during the past 12 years. Patients and methods We underwent 79 CBT until 2008. Fifty-seven patients were available for assessing EBV serology. The mean age of patients was 63 months (range, 6m-28y5m). The underlying disease was hematologic malignancy (n=27), hematologic non-malignancy (n=10), autoimmune disease (n=2), solid tumor (n=7), and EBV-associated T/NK-LPD (n=11). Results Forty-six (80.7%) of the 57 recipients were EBV seropositive before CBT (sero+/). Nineteen (41.3%) of 46 EBV seropositive recipients before CBT became EBV seronegative after CBT (sero+/sero-). Five patients (8.8%) developed EBV-associated post-transplantation LPD. Three of the 5 LPD patients arose from 27 patients of sero+/sero+ group, and the time of onset of LPD was 2-6 months after CBT. Two of them died of LPD. The remaining 2 patients arose from 19 patients of sero+/sero- group, and the time of onset of LPD was 6-9 months. These 2 patients were successfully treated. None of the 11 patients (6 in sero-/sero- group and 5 in sero-/sero+ group) developed LPD. Discussion Among EBV seropositive patients, about 60% of them remained seropositive (endogenous infection group), and 40% of them became seronegative after CBT. The latter group is likely to experience exogenous infection (secondary primary infection). In both instances, incidence of LPD seems to be quite high. Therefore regular monitoring of EBV serology and EBV-DNA load after CBT should be essentially required for all CBT patients. Disclosures No relevant conflicts of interest to declare.

The functional immaturity of dendritic cells can be relevant to increased tolerance associated with cord blood transplantation

Transfusion ◽  
2007 ◽  
Vol 47 (2) ◽  
pp. 272-279 ◽  
Author(s):  
Araceli Encabo ◽  
Pilar Solves ◽  
Francisco Carbonell-Uberos ◽  
Maria Dolores Miñana
Keyword(s):  
Dendritic Cells ◽  
Cord Blood ◽  
Cord Blood Transplantation ◽  
Blood Transplantation ◽  
Functional Immaturity
Sign in / Sign up

Export Citation Format

Share Document